Keystone Dental Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
- Q3 revenue increased 18.9% year-over-year to $16.8M, including $11.9M from the U.S. Check-Cap shareholders to vote on proposed Business Combination Agreement with Keystone Dental at Annual General Meeting on Monday, December 18th, 2023 IRVINE, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings (“Keystone Dental” or the “Company”), a pioneer in dental implant technology, announced today financial results and provided a corporate update for the third quarter and nine months ended September 30, 2023.
- 11/28/2023
|
Check-Cap Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
- Check-Cap shareholders to vote on proposed Business Combination Agreement with Keystone Dental at Annual General Meeting on Monday, December 18 th ISFIYA, Israel , Nov. 27, 2023 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), today announced financial results and provided a corporate update for the third quarter and nine months ended September 30, 2023.
- 11/27/2023
|
Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement
- Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone's comprehensive portfolio of implants, arches and other tooth replacement solutions
- 08/16/2023
|
Check-Cap Reports Second Quarter 2023 Financial Results
- ISFIYA, Israel, Aug. 4, 2023 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), today announced financial results for the second quarter and six months ended June 30, 2023.
- 08/04/2023
|
SYMETRYX CORP INCREASES NON-BINDING OFFER TO ACQUIRE CHECK-CAP TO $4.60 PER SHARE
- TORONTO, ON , July 25, 2023 /PRNewswire/ - Today, Symetryx Corporation ("Symetryx") announced an increase in price per share for our non-binding proposal to acquire common shares of Check-Cap LTD (NASDAQ: CHEK) ("Check"). In our press release dated July 18, 2023 ("July 18 Press Release"), Symetryx announced a non-binding offer to purchase Check common shares at $4.35 per share in cash.
- 07/25/2023
|
3 Medical Instruments Stocks With Potential to Outperform
- Here we discuss ShockWave Medical (SWAV), CheckCap (CHEK) and Biosig Technologies (BSGM) that have the potential to outperform their industry going forward.
- 09/08/2022
|
FDA Gives Green To Check-Cap's Pivotal Study For Capsule-Based Colorectal Cancer Screening Test
- The FDA has approved Check-Cap Ltd's (NASDAQ: CHEK) amended Investigational Device Exemption (IDE) application to initiate the U.S. pivotal study of C-Scan. The U.S. pivotal study consists of two parts.
- 02/07/2022
|
5 Penny Stocks To Buy According To Analysts & Price Targets Up To 175%
- Some of the best penny stocks 2021 has offered were some of… The post 5 Penny Stocks To Buy According To Analysts & Price Targets Up To 175% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/02/2021
|
Top Penny Stocks To Buy For Under $5 On WeBull
- A penny stocks list for the end of October The post Top Penny Stocks To Buy For Under $5 On WeBull appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/20/2021
|
Best Biotech Penny Stocks to Buy in July 2021? 6 For Your Watchlist
- Biotech penny stocks are in focus; here's 4 to watch right now The post Best Biotech Penny Stocks to Buy in July 2021? 6 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/12/2021
|
CHEK Stock Price Falls Over 10%: Why It Happened
- The stock price of Check Cap Ltd (NASDAQ: CHEK) fell by over 10% during intraday trading. This is why it happened.
- 06/30/2021
|
Check-Cap Ltd. Announces $35 Million Registered Direct Offering
- ISFIYA, Israel, June 30, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test, to detect polyps before they may transform into colorectal cancer (CRC), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 25,925,926 of the Company's ordinary shares and accompanying short-term warrants to purchase up to an aggregate of 25,925,926 of the Company's ordinary shares in a registered direct offering.
- 06/30/2021
|
Mark a Major Medical Milestone with Check-Cap
- Why should you check out CHEK stock? An FDA approval, along with an impressive year-end capital position, provide a solid case for Check-Cap.
- 03/30/2021
|
Check-Cap Reports Fourth Quarter and Full Year 2020 Financial Results
- ISFIYA, Israel, March 19, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free, screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results for the fourth quarter and full year ended December 31, 2020.
- 03/19/2021
|
CHEK Stock Price Falls Over 10% Pre-Market: Why It Happened
- The stock price of Check Cap Ltd (NASDAQ: CHEK) fell by over 10% pre-market. This is why it happened.
- 03/16/2021
|
CHEK Stock: The Big FDA News That Has Check-Cap Shares Skyrocketing Today
- Check-Cap (CHEK) stock is heading higher on Monday after the company announced approval from the FDA for one of its devices. The post CHEK Stock: The Big FDA News That Has Check-Cap Shares Skyrocketing Today appeared first on InvestorPlace.
- 03/15/2021
|
CHEK Stock Price Increases Over 130% Pre-Market: Why It Happened
- The stock price of Check Cap Ltd (NASDAQ: CHEK) has increased by over 130% pre-market. This is why it happened.
- 03/15/2021
|
FDA Signs Off Check-Cap's Pivotal Study For Capsule-Based Colorectal Cancer Screening Technology
- Check-Cap Ltd (NASDAQ: CHEK) stock is moving higher on heavy volume in the premarket session after the FDA approved its Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. C-Scan is the company's capsule-based screening technology to detect polyps before they may transform into colorectal cancer (CRC) to enable early intervention and cancer prevention.
- 03/15/2021
|
Check-Cap: Come Back In A Year
- The technology appears safe, but performance versus standard of care requires a larger, expensive study. It will take a couple years to get readouts from the pivotal US study, providing a lack of catalyst.
- 01/28/2021
|
Check-Cap Ltd.: 6 Things for Potential CHEK Stock Investors to Know About the Biotech Company
- Check-Cap Ltd. (CHEK) stock is on the rise Monday despite a lack of news from the maker of the C-Scan colorectal cancer screening device.
- 01/04/2021
|
Check-Cap Reports Second Quarter 2020 Financial Results and Corporate Highlights
- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer, today announced financial results for the second quarter and six months ended June 30, 2020.
- 08/06/2020
|
Check-Cap Announces Exercise of Warrants For $9.6 Million Gross Proceeds
- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into cancer, today announced that it has entered into a definitive agreement with several existing institutional investors for the exercise of certain outstanding warrants to purchase up to an aggregate of 16,054,223 of its ordinary shares at a reduced exercise price of $0.60 per share. The warrants being exercised were issued by Check-Cap on several dates from November 2017 through May 2020 and have exercise prices ranging from $15.00 to $0.80 per share.
- 07/23/2020
|
We're A Little Worried About Check-Cap's (NASDAQ:CHEK) Cash Burn Rate
- There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- 06/07/2020
|
Check-Cap Announces Receipt of Nasdaq Minimum Bid Price Notification
- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
- 06/05/2020
|
Check-Cap Reports First Quarter 2020 Financial Results and Provides Corporate Update
- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer, today announced financial results for the first quarter ended March 31, 2020.
- 05/27/2020
|
Check-Cap Ltd. Announces $3.0 Million Registered Direct Offering
- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free screening test to detect polyps before they transform into colorectal cancer, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 5,000,000 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering. Check-Cap has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 5,000,000 ordinary shares. The offering is expected to close on or about May 13, 2020, subject to satisfaction of customary closing conditions.
- 05/09/2020
|
Check-Cap Ltd. Announces $4.5 Million Registered Direct Offering
- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free screening test to detect polyps before they transform into colorectal cancer, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,500,001 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering. Check-Cap has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 7,500,001 ordinary shares. The offering is expected to close on or about May 4, 2020, subject to satisfaction of customary closing conditions.
- 04/30/2020
|
Stocks That Hit 52-Week Lows On Monday
- Monday morning, 15 companies reached new 52-week lows.
Areas of Interest:
The largest company by market cap to set a new 52-week low was Fomento Economico (NYSE: FMX)...
- 04/20/2020
|
Energy stocks among top premarket losers
- Check-Cap (NASDAQ:CHEK) -54% on $4M direct offering.Invesco Mortgage Capital (NYSE:IVR) -32%.Akazoo S.A. (NASDAQ:SONG) -24%.Penn Virginia (NASDAQ:PVAC) -17%.California Resources (NYSE:CRC) -17%.Matado
- 04/20/2020
|
Check-Cap Ltd. Announces $4.0 Million Registered Direct Offering
- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free screening test to detect polyps before they transform into colorectal cancer, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 6,666,669 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering. Check-Cap has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 6,666,669 ordinary shares. The offering is expected to close on or about April 22, 2020, subject to satisfaction of customary closing conditions.
- 04/20/2020
|
Global Market Overview on Disposable Medical Sensors (2019 to 2026) - Featuring Abbott, Broadcom & First Sensor Among Others
- Dublin, April 17, 2020 -- The "Disposable Medical Sensors - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. Rising.
- 04/17/2020
|
Check-Cap Ltd. (CHEK) Upgraded to Buy: What Does It Mean for the Stock?
- Check-Cap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 04/16/2020
|
Check-Cap Provides Update on COVID-19 Pandemic Impact on Operational and Clinical Activities
- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free screening test to detect polyps before they transform into colorectal cancer, today provided an update on the impact of the global COVID-19 coronavirus pandemic on the Company's operational and clinical activities.
- 04/06/2020
|
Check-Cap Reports Fourth Quarter and Full Year 2019 Financial Results
- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they transform into colorectal cancer, today announced financial results for the fourth quarter and full year ended December 31, 2019.
- 03/06/2020
|
Check-Cap Announces Positive Results from U.S. Pilot Study of C-Scan® System
- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and only preparation-free ingestible scanning capsule based system for the prevention of colorectal cancer through the detection of precancerous polyps, today announced positive results from the Company's pilot study of the C-Scan® System in the U.S.
- 12/30/2019
|
Is Check-Cap Ltd. (CHEK) Going To Burn These Hedge Funds ?
- How do we determine whether Check-Cap Ltd. (NASDAQ:CHEK) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that […]
- 12/23/2019
|
Check-Cap Announces $4.75 Million Private Placement
- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and only preparation-free ingestible scanning capsule based system for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that the Company has entered into definitive agreements with certain investors to purchase approximately $4.75 million of its ordinary shares in a private placement.
- 12/20/2019
|
What Kind Of Shareholder Owns Most Check-Cap Ltd. (NASDAQ:CHEK) Stock?
- The big shareholder groups in Check-Cap Ltd. (NASDAQ:CHEK) have power over the company. Institutions will often hold...
- 11/11/2019
|
Check-Cap Reports Third Quarter 2019 Financial Results and Corporate Highlights
- Successfully launched U.S. pilot study and reported positive final results from post-CE approval study of the C-Scan® System ISFIYA, Israel , Nov. 6, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" ...
- 11/06/2019
|
Check-Cap to Present at the Dawson James 5th Annual Small Cap Growth Conference
- ISFIYA, Israel , Oct. 24, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...
- 10/24/2019
|
Check-Cap Expands Leadership Team With Appointment of Dr. Vardit Segal as Vice President of Clinical Affairs
- ISFIYA, Israel , Sept. 25, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics ...
- 09/25/2019
|
Check-Cap to Present at the H.C. Wainwright 21st Annual Global Investment Conference
- ISFIYA, Israel , Sept. 3, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...
- 09/03/2019
|
Check-Cap and GE Healthcare Announce Completion of Manufacturing Line Transfer Implementation and Qualification for the C-Scan® System Operated by GE Healthcare
- GE Healthcare facility in Chicago to support clinical investigation needs of the C-Scan® System in the U.S. ISFIYA, Israel , Aug. 19, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") ...
- 08/19/2019
|
Check-Cap Reports Second Quarter 2019 Financial Results and Corporate Highlights
- Reported positive final results from post-CE approval study of the C-Scan® System ISFIYA, Israel , Aug. 7, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: ...
- 08/07/2019
|
Check-Cap Announces Positive Final Results from Its Post-CE Approval Study of the C-Scan® System
- ISFIYA, Israel, July 9, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free capsule based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system. The study included 90 evaluable patients who either had known polyps or were considered to be of average risk.
- 07/09/2019
|
